MedPage Today July 16, 2025
The initiative was designed to broaden access to expensive gene therapies
The Centers for Medicare & Medicaid Services (CMS) announced Tuesday that 33 states, as well as the District of Columbia and Puerto Rico, have agreed to participate in the Cell and Gene Therapy (CGT) Access Model, which is designed to broaden access to these expensive therapies for patients with sickle cell disease (SCD).
The model was initially launched by the Biden administration in February 2023, and CMS announced that SCD would be the first focus of the model the following January.
This is the first time that the federal government has negotiated outcomes-based agreements with cell and gene therapy manufacturers on behalf of state Medicaid agencies, CMS said, with...
Today's Sponsors
Today's Sponsor